CTLA4 and breast cancer: By using spontaneous mouse models of primary and metastatic breast cancer the authors demonstrated that anti-PD1 plus anti-CTLA4 immunotherapy increased IL-5 production by CD4+ T cells, which stimulated eosinophilopoiesis from the bone marrow and systemic eosinophil expansion, but not intratumoral infiltration.